PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development candidate for its oral KAT6A degrader program and remains on track to file an IND in the first half of 2026 Current cash runway into the second quarter of 2026 with $77.3 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2025  WILMINGTON, Del., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for second quarter ended June 30, 2025, and provided an update on its clinical development pipeline and other corporate developments.

08/14/2025

Two Sigma Investments LP grew its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) by 307.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 231,839 shares of the company’s stock after acquiring an additional 174,906 shares during the quarter. Two Sigma Investments LP owned 0.42% of Prelude Therapeutics worth $296,000 as of its most recent SEC filing. A number of other hedge funds also recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Prelude Therapeutics in the 4th quarter worth approximately $26,000. JPMorgan Chase & Co. raised its holdings in shares of Prelude Therapeutics by 925.0% in the 4th quarter. JPMorgan Chase & Co. now owns 61,149 shares of the company’s stock worth $78,000 after buying an additional 55,183 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Prelude Therapeutics by 747.6% in the 4th quarter. Deutsche Bank AG now owns 123,899 shares of the company’s stock worth $159,000 after buying an additional 109,281 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Prelude Therapeutics by 1,289.8% in the 4th quarter. Rhumbline Advisers now owns 166,830 shares of the company’s stock worth $213,000 after buying an additional 154,826 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Prelude Therapeutics by 526.3% in the 4th quarter. Two Sigma Advisers LP now owns 300,000 shares of the company’s stock worth $382,000 after buying an additional 252,100 shares in the last quarter. Institutional investors own 79.72% of the company’s stock. Analyst Upgrades and Downgrades A number of equities analysts have recently issued reports on PRLD shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a report on Monday, May 5th. JMP Securities reissued a “market outperform” rating and issued a $4.00 target price on shares of Prelude Therapeutics in a report on Tuesday, April 29th. View Our Latest Research Report on Prelude Therapeutics Insider Activity at Prelude Therapeutics In other Prelude Therapeutics news, insider Andrew Combs purchased 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $0.69 per share, with a total value of $69,000.00. Following the acquisition, the insider now directly owns 480,123 shares of the company’s stock, valued at approximately $331,284.87. This trade represents a 26.31% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Krishna Vaddi bought 675,000 shares of the stock in a transaction dated Tuesday, March 25th. The stock was purchased at an average cost of $0.69 per share, with a total value of $465,750.00. Following the completion of the purchase, the chief executive officer now directly owns 1,999,296 shares in the company, valued at approximately $1,379,514.24. This trade represents a 50.97% increase in their position. The disclosure for this purchase can be found here. Insiders own 63.90% of the company’s stock. Prelude Therapeutics Price Performance PRLD stock opened at $1.08 on Wednesday. The business has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.93. Prelude Therapeutics Incorporated has a fifty-two week low of $0.61 and a fifty-two week high of $6.80. The stock has a market capitalization of $60.98 million, a price-to-earnings ratio of -0.61 and a beta of 1.25. Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.05. On average, equities analysts expect that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year. Prelude Therapeutics Company Profile (Free Report) Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.

06/11/2025